Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Clinical trial NCT02668770 · TERMINATED

Trial details

NCT number: NCT02668770
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Cancers Melanoma

Start date: 2016-05-11
Primary completion: 2025-11-05
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.